ClinicalTrials.gg
CompletedNCT00708682Updated Oct 25, 2011Results posted

Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 9 sites in Mexico. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-25.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Non-randomized
Ages
42 Days to 98 Days
Sex
All
01

Study summary

The purpose of this study will be to evaluate safety, tolerability and immunogenicity of 13-valent pneumococcal vaccine in healthy infants given with routine pediatric vaccinations in Mexico.

02

Conditions studied

  • Vaccines, Pneumococcal
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone
  • Able to complete three blood draws during study
  • At least 3.5 kg at enrollment

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination (except Hepatitis, BCG), or allergic reaction to vaccines
  • Immune deficiency, bleeding disorder or significant chronic medical condition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    A

    Biological: 13-valent pneumococcal conjugate vaccine

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (Mcg/mL), 1 Month After the Infant Series

    Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL, along with the corresponding 95 percent confidence interval (95% CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: 1 month after the infant series (7 months of age)

Secondary outcomes

  1. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35mcg/mL, 1 Month After Dose 2 of the Infant Series

    Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL, along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: 1 month after dose 2 of the infant series (5 months of age)

  2. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Concentration ≥0.35mcg/mL, 1 Month After the Toddler Dose

    Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL, along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: 1 month after the toddler dose (13 months of age)

Other outcomes

  1. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody After Dose 2 of the Infant Series

    Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw.

    Time frame: Dose 2 of infant series (4 months of age)

  2. GMC for Serotype-specific Pneumococcal IgG Antibody After Dose 3 of the Infant Series

    Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 7vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw.

    Time frame: Dose 3 of infant series (6 months of age)

  3. GMC for Serotype-specific Pneumococcal IgG Antibody After the Toddler Dose

    Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 7vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data after the toddler dose and after the third dose of the infant series.

    Time frame: Toddler Dose (12 months of age)

  4. Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0cm); Moderate (2.5 to 7.0cm); Severe (greater than \[\>\] 7.0cm). Participants may be represented in more than 1 category.

    Time frame: Within 4 days after dose 1 of Infant Series (2 months of age)

  5. Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0cm); Moderate (2.5 to 7.0cm); Severe (\>7.0cm). Participants may be represented in more than 1 category.

    Time frame: Within 4 days after dose 2 of Infant Series (4 months of age)

  6. Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0cm); Moderate (2.5 to 7.0cm); Severe (\>7.0cm). Participants may be represented in more than 1 category.

    Time frame: Within 4 days after dose 3 (6 months of age)

  7. Percentage of Participants Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0cm); Moderate (2.5 to 7.0cm); Severe (\>7.0cm). Participants may be represented in more than 1 category.

    Time frame: Within 4 days after toddler dose (12 months of age)

  8. Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (2 Months of Age)

    Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 4 days after dose 1 of Infant Series (2 months of age)

  9. Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 Months of Age)

    Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 4 days after dose 2 of Infant Series (4 months of age)

  10. Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (6 Months of Age)

    Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 4 days after dose 3 of Infant Series (6 months of age)

  11. Percentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 Months of Age)

    Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 4 days after toddler dose (12 months of age)

07

Results

Posted Feb 25, 2011

Participant flow

Infant Series
Participant flow — Infant Series
Milestone13vPnC
Started225
Vaccinated dose 1223
Vaccinated dose 2214
Vaccinated dose 3194
Completed192
Not completed33
Withdrew: Adverse event1
Withdrew: Lost to follow-up4
Withdrew: Protocol violation1
Withdrew: Parent/legal guardian request6
Withdrew: Failed to return2
Withdrew: Other19
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC
Started192
Completed191
Not completed1
Withdrew: Parent/legal guardian request1
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC
Started191
Completed183
Not completed8
Withdrew: Parent/legal guardian request1
Withdrew: Lost to follow-up3
Withdrew: Failed to return4

Outcome measures

PrimaryPercentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (Mcg/mL), 1 Month After the Infant Series

Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL, along with the corresponding 95 percent confidence interval (95% CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
1 month after the infant series (7 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (Mcg/mL), 1 Month After the Infant Series
Percentage of participants13vPnC
Common serotypes - serotype 4100.0 (97.9 to 100.0)
Common serotypes - serotype 6B97.7 (94.1 to 99.4)
Common serotypes - serotype 9V98.2 (94.9 to 99.6)
Common serotypes - serotype 1498.8 (95.8 to 99.9)
Common serotypes - serotype 18C98.8 (95.8 to 99.9)
Common serotypes - serotype 19F98.2 (95.0 to 99.6)
Common serotypes - serotype 23F92.9 (87.9 to 96.3)
Additional serotypes - serotype 199.4 (96.8 to 100.0)
Additional serotypes - serotype 394.1 (89.4 to 97.1)
Additional serotypes - serotype 598.2 (95.0 to 99.6)
Additional serotypes - serotype 6A98.8 (95.8 to 99.9)
Additional serotypes - serotype 7F98.8 (95.8 to 99.9)
Additional serotypes - serotype 19A99.4 (96.8 to 100.0)
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35mcg/mL, 1 Month After Dose 2 of the Infant Series

Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL, along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
1 month after dose 2 of the infant series (5 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35mcg/mL, 1 Month After Dose 2 of the Infant Series
Percentage of participants13vPnC
Common serotypes - serotype 4100.0 (98.1 to 100.0)
Common serotypes - serotype 6B80.9 (74.7 to 86.2)
Common serotypes - serotype 9V95.9 (92.1 to 98.2)
Common serotypes - serotype 1499.0 (96.3 to 99.9)
Common serotypes - serotype 18C93.3 (88.9 to 96.4)
Common serotypes - serotype 19F98.5 (95.5 to 99.7)
Common serotypes - serotype 23F77.9 (71.5 to 83.6)
Additional serotypes - serotype 198.5 (95.6 to 99.7)
Additional serotypes - serotype 396.4 (92.7 to 98.5)
Additional serotypes - serotype 597.4 (94.1 to 99.2)
Additional serotypes - serotype 6A94.9 (90.8 to 97.5)
Additional serotypes - serotype 7F99.0 (96.3 to 99.9)
Additional serotypes - serotype 19A99.5 (97.2 to 100.0)
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Concentration ≥0.35mcg/mL, 1 Month After the Toddler Dose

Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL, along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
1 month after the toddler dose (13 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Concentration ≥0.35mcg/mL, 1 Month After the Toddler Dose
Percentage of participants13vPnC
Common serotypes - serotype 4100.0 (97.6 to 100.0)
Common serotypes - serotype 6B99.4 (96.5 to 100.0)
Common serotypes - serotype 9V100.0 (97.6 to 100.0)
Common serotypes - serotype 14100.0 (97.6 to 100.0)
Common serotypes - serotype 18C100.0 (97.6 to 100.0)
Common serotypes - serotype 19F100.0 (97.6 to 100.0)
Common serotypes - serotype 23F99.4 (96.5 to 100.0)
Additional serotypes - serotype 1100.0 (97.6 to 100.0)
Additional serotypes - serotype 396.7 (92.5 to 98.9)
Additional serotypes - serotype 5100.0 (97.6 to 100.0)
Additional serotypes - serotype 6A100.0 (97.6 to 100.0)
Additional serotypes - serotype 7F100.0 (97.6 to 100.0)
Additional serotypes - serotype 19A100.0 (97.6 to 100.0)
Other pre-specifiedGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody After Dose 2 of the Infant Series

Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw.

Time frame:
Dose 2 of infant series (4 months of age)
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody After Dose 2 of the Infant Series
mcg/mL13vPnC
Common serotypes - serotype 43.54 (3.16 to 3.97)
Common serotypes - serotype 6B0.84 (0.71 to 0.98)
Common serotypes - serotype 9V1.82 (1.60 to 2.08)
Common serotypes - serotype 145.54 (4.72 to 6.50)
Common serotypes - serotype 18C1.80 (1.56 to 2.07)
Common serotypes - serotype 19F4.14 (3.59 to 4.78)
Common serotypes - serotype 23F0.84 (0.71 to 0.99)
Additional serotypes - serotype 13.41 (3.00 to 3.89)
Additional serotypes - serotype 31.11 (1.01 to 1.23)
Additional serotypes - serotype 51.89 (1.67 to 2.13)
Additional serotypes - serotype 6A1.86 (1.60 to 2.16)
Additional serotypes - serotype 7F2.98 (2.70 to 3.29)
Additional serotypes - serotype 19A3.52 (3.07 to 4.03)
Other pre-specifiedGMC for Serotype-specific Pneumococcal IgG Antibody After Dose 3 of the Infant Series

Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 7vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw.

Time frame:
Dose 3 of infant series (6 months of age)
Reported as:
Geometric mean · mcg/mL
GMC for Serotype-specific Pneumococcal IgG Antibody After Dose 3 of the Infant Series
mcg/mL13vPnC
Common serotypes - serotype 43.48 (3.12 to 3.88)
Common serotypes - serotype 6B5.02 (4.27 to 5.90)
Common serotypes - serotype 9V2.34 (2.11 to 2.60)
Common serotypes - serotype 149.35 (8.07 to 10.82)
Common serotypes - serotype 18C2.50 (2.23 to 2.81)
Common serotypes - serotype 19F3.75 (3.28 to 4.29)
Common serotypes - serotype 23F1.83 (1.55 to 2.17)
Additional serotypes - serotype 14.23 (3.73 to 4.79)
Additional serotypes - serotype 31.17 (1.03 to 1.33)
Additional serotypes - serotype 53.11 (2.75 to 3.52)
Additional serotypes - serotype 6A4.08 (3.56 to 4.68)
Additional serotypes - serotype 7F3.71 (3.34 to 4.12)
Additional serotypes - serotype 19A4.19 (3.71 to 4.74)
Other pre-specifiedGMC for Serotype-specific Pneumococcal IgG Antibody After the Toddler Dose

Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 7vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data after the toddler dose and after the third dose of the infant series.

Time frame:
Toddler Dose (12 months of age)
Reported as:
Geometric mean · mcg/mL
GMC for Serotype-specific Pneumococcal IgG Antibody After the Toddler Dose
mcg/mL13vPnC
Common serotypes - serotype 45.10 (4.41 to 5.89)
Common serotypes - serotype 6B15.41 (12.92 to 18.38)
Common serotypes - serotype 9V3.76 (3.29 to 4.29)
Common serotypes - serotype 1410.62 (9.16 to 12.32)
Common serotypes - serotype 18C3.93 (3.45 to 4.48)
Common serotypes - serotype 19F11.33 (9.68 to 13.26)
Common serotypes - serotype 23F5.70 (4.81 to 6.77)
Additional serotypes - serotype 15.86 (5.08 to 6.75)
Additional serotypes - serotype 31.62 (1.42 to 1.84)
Additional serotypes - serotype 54.75 (4.18 to 5.40)
Additional serotypes - serotype 6A11.64 (9.93 to 13.64)
Additional serotypes - serotype 7F5.81 (5.18 to 6.51)
Additional serotypes - serotype 19A8.95 (7.84 to 10.23)
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0cm); Moderate (2.5 to 7.0cm); Severe (greater than \[\>\] 7.0cm). Participants may be represented in more than 1 category.

Time frame:
Within 4 days after dose 1 of Infant Series (2 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)
Percentage of participants13vPnC
Tenderness: Any63.5
Tenderness: Significant12.4
Swelling: Any31.2
Swelling: Mild25.1
Swelling: Moderate11.9
Swelling: Severe0
Redness: Any33.8
Redness: Mild27.9
Redness: Moderate10.6
Redness: Severe0
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0cm); Moderate (2.5 to 7.0cm); Severe (\>7.0cm). Participants may be represented in more than 1 category.

Time frame:
Within 4 days after dose 2 of Infant Series (4 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)
Percentage of participants13vPnC
Tenderness: Any69.4
Tenderness: Significant12.6
Swelling: Any29.9
Swelling: Mild20.0
Swelling: Moderate13.3
Swelling: Severe0
Redness: Any28.9
Redness: Mild19.5
Redness: Moderate12.3
Redness: Severe0
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0cm); Moderate (2.5 to 7.0cm); Severe (\>7.0cm). Participants may be represented in more than 1 category.

Time frame:
Within 4 days after dose 3 (6 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)
Percentage of participants13vPnC
Tenderness: Any61.3
Tenderness: Significant15.4
Swelling: Any29.4
Swelling: Mild19.0
Swelling: Moderate14.6
Swelling: Severe0
Redness: Any31.8
Redness: Mild20.9
Redness: Moderate13.9
Redness: Severe0
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0cm); Moderate (2.5 to 7.0cm); Severe (\>7.0cm). Participants may be represented in more than 1 category.

Time frame:
Within 4 days after toddler dose (12 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)
Percentage of participants13vPnC
Tenderness: Any43.7
Tenderness: Significant3.8
Swelling: Any21.3
Swelling: Mild8.1
Swelling: Moderate15.8
Swelling: Severe0
Redness: Any22.0
Redness: Mild8.8
Redness: Moderate15.7
Redness: Severe0
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (2 Months of Age)

Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 4 days after dose 1 of Infant Series (2 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (2 Months of Age)
Percentage of participants13vPnC
Fever ≥38 degrees C but ≤39 degrees C7.0
Fever >39 degrees C but ≤40 degrees C0
Fever >40 degrees C0
Decreased appetite31.0
Irritability69.8
Increased sleep37.2
Decreased sleep32.8
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 Months of Age)

Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 4 days after dose 2 of Infant Series (4 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 Months of Age)
Percentage of participants13vPnC
Fever ≥38 degrees C but ≤39 degrees C18.5
Fever >39 degrees C but ≤40 degrees C0.6
Fever >40 degrees C0
Decreased appetite29.3
Irritability62.2
Increased sleep24.5
Decreased sleep35.1
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (6 Months of Age)

Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 4 days after dose 3 of Infant Series (6 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (6 Months of Age)
Percentage of participants13vPnC
Fever ≥38 degrees C but ≤39 degrees C18.3
Fever >39 degrees C but ≤40 degrees C2.2
Fever >40 degrees C0
Decreased appetite25.7
Irritability63.2
Increased sleep22.9
Decreased sleep37.3
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 Months of Age)

Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 4 days after toddler dose (12 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 Months of Age)
Percentage of participants13vPnC
Fever ≥38 degrees C but ≤39 degrees C23.0
Fever >39 degrees C but ≤40 degrees C0
Fever >40 degrees C0
Decreased appetite33.8
Irritability46.7
Increased sleep17.9
Decreased sleep22.0

Adverse events

Collected over Baseline through 1 Month after last study vaccination (13 Months). Local reactions and systemic events assessed within 4 days of dose: Infant Series Dose 1=2 months of age; Dose 2=4 months of age; Dose 3=6 months of age; Toddler Dose=12 months of age.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infant Series 13vPnC—3/223 (1.3%)182/223 (81.6%)
After the Infant Series 13vPnC—3/223 (1.3%)3/223 (1.3%)
Toddler Dose 13vPnC—2/191 (1%)96/191 (50.3%)
Most frequent serious events
Most frequent serious events
EventInfant Series 13vPnCAfter the Infant Series 13vPnCToddler Dose 13vPnC
Acute sinusitisInfections and infestations0/2230/2231/191
Seizure anoxicNervous system disorders0/2230/2231/191
MyocarditisCardiac disorders1/2230/2230/191
DiarrhoeaGastrointestinal disorders1/2230/2230/191
PyrexiaGeneral disorders1/2231/2230/191
BronchiolitisInfections and infestations1/2230/2230/191
AngioedemaSkin and subcutaneous tissue disorders1/2230/2230/191
Kawasaki's diseaseVascular disorders1/2230/2230/191
PneumoniaInfections and infestations0/2231/2230/191
Breath holdingPsychiatric disorders0/2231/2230/191
Most frequent other events
Showing 10 of 109
Most frequent other events
EventInfant Series 13vPnCAfter the Infant Series 13vPnCToddler Dose 13vPnC
IrritabilityGeneral disorders148/212—71/152
Tenderness (any)Skin and subcutaneous tissue disorders136/196——
Tenderness (any)Skin and subcutaneous tissue disorders134/211—66/151
IrritabilityGeneral disorders103/163——
IrritabilityGeneral disorders120/193——
Tenderness (any)Skin and subcutaneous tissue disorders100/163——
Decreased sleepGeneral disorders56/150——
Increased sleepGeneral disorders77/207—25/140
Decreased sleepGeneral disorders66/188——
Redness (any)Skin and subcutaneous tissue disorders69/204—31/141

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC
Mean2.1 ± 0.5
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC
Female109
Male116
08

Study locations

9 sites
  • Guadalajara, Jalisco 44080, Mexico
  • Morelia, Michoacan 58070, Mexico
  • Cuernavaca, Morelos 62508, Mexico
  • Monterrey, Nuevo Leon 64460, Mexico
  • Merida, Yucatan 9700, Mexico
  • Distrio Federal, 14080, Mexico
  • Distrio Federal, 4530, Mexico
  • Oaxaca, 71220, Mexico
  • Puebla, 72190, Mexico
09

References and documents

Publications

  • Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ, Snape MD, Martinon-Torres F, Gruber WC, Patterson S, Thompson A, Gurtman A, Paradiso P, Scott DA. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine. 2013 Oct 1;31(42):4765-74. doi: 10.1016/j.vaccine.2013.08.009. Epub 2013 Aug 16. PubMed 23965217 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2008
First posted
Jul 2, 2008
Start
Jul 2008
Primary completionActual
May 2010
CompletionActual
May 2010
Results first posted
Feb 25, 2011
Last update
Oct 25, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00708682
Responsible party
Sponsor
First posted
Jul 2, 2008
Start date
Jul 2008
Primary completion
May 2010
Completion
May 2010
Results posted
Feb 25, 2011
Last update
Oct 25, 2011

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion